Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel + prednisone with or without lenalidomide in metastatic castration-resistant prostate cancer
2008-007969-23Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Sep 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lenalidomide in prostate cancer (PCa) (2 arms), sponsored by Celgene Corporation. Primary endpoint: Overall Survival. Started Sep 2009; status: completed.
02
Drugs
lenalidomide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2008-007969-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007969-23.